Elon Musk’s Neuralink has reached a new milestone with its latest technological breakthrough, the Blindsight device, receiving approval from the U.S. Food and Drug Administration (FDA).

This advanced brain-machine interface is designed to restore vision for individuals who have lost both eyes and their optic nerve.

Musk shared on social media, “The Blindsight device from Neuralink will enable even those who have lost both eyes and their optic nerve to see.”

He emphasized that the vision produced initially would resemble low-resolution graphics, akin to the Atari era of video games, with the potential for significant improvement over time.

The Blindsight device from Neuralink will enable even those who have lost both eyes and their optic nerve to see.

Provided the visual cortex is intact, it will even enable those who have been blind from birth to see for the first time.

To set expectations correctly, the vision… https://t.co/MYLHNcPrw6 pic.twitter.com/RAenDpd3fx

— Elon Musk (@elonmusk) September 17, 2024

Musk has indicated that the Blindsight device could surpass natural vision, potentially allowing users to see infrared, ultraviolet, or even radar wavelengths.

“To set expectations correctly, the vision will at first be low resolution, like Atari graphics, but eventually it has the potential to be better than natural vision and enable you to see in infrared, ultraviolet, or even radar wavelengths,” Musk explained. This innovation positions Neuralink at the forefront of cutting-edge neural technology and medical advancement.

The approval from the FDA marks a critical step in bringing this technology closer to those in need, paving the way for future clinical trials and broader applications in restoring vision.